Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Erica Brivio, Christophe F. Chantrain, Tanja A. Gruber, Adriana Thano, Fanny Rialland, Audrey Contet, Sarah Elitzur, Luciano Dalla-Pozza, Krisztián Miklós Kállay, Chi kong Li, Motohiro Kato, Inna Markova, Kjeld Schmiegelow, Nicole Bodmer, Erin H. Breese, Raoull Hoogendijk, Rob Pieters, Christian Michel Zwaan*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

Original languageEnglish
Pages (from-to)1172-1177
Number of pages6
JournalBritish Journal of Haematology
Volume193
Issue number6
Early online date2 Feb 2021
DOIs
Publication statusPublished - Jun 2021

Bibliographical note

Funding Information:
No funding source to disclose. All authors have contributed to the manuscript in significant ways: CMZ and EB designed the study; CFC, TAG, FR, AC, SE, LD-P, KMK, CL, MK, IM, KS, NB and EHB contributed in patient treatment and data collection and interpretation; EB, RH, AT and CMZ contributed to collection and assembly of data and provided data analysis and interpretation; CMZ and EB contributed also to the literature search and editing the manuscript. All authors have both reviewed and agreed on the manuscript content. The authors would like to thank Andrea Biondi and the iBFM network for sharing the study within the collaborative group centres.

Publisher Copyright:
© 2021 British Society for Haematology and John Wiley & Sons Ltd.

Fingerprint

Dive into the research topics of 'Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series'. Together they form a unique fingerprint.

Cite this